This study not only shows that PALM2 is upregulated in esophageal cancer and is an independent risk factor for poor prognosis in patients with esophageal cancer (Fig. 2) but also demonstrates that PALM2 activates ezrin (Fig. 6, D–F) and subsequently promotes the malignant progression of esophageal cancer cells (Fig. 6C). Here, EZR is linked to esophageal cancer.